Billionaire Druckenmiller makes cancer stock his #1 buy for a reason

Legendary billionaire investor Stanley Druckenmiller has made cancer-testing company Natera his primary stock purchase, despite it being a lesser-known name in the industry. The Duquesne Family Office, which manages his investments, holds a dominant stake in Natera, comprising 16.6% of its reported portfolio as of the second quarter of 2026.

Druckenmiller continues to add shares to the position, even as the stock trades near record highs, indicating strong confidence in the company's growth potential. Natera's main product, Signatera, is a blood test that detects cancer recurrence early, which appeals to hospitals regardless of economic conditions. In the second quarter of 2026, Natera reported a 37.7% revenue increase, driven by a 57.2% rise in oncology test volume.

Despite operating at a loss, the company expects to achieve positive cash flow by the end of the fiscal year. Druckenmiller's large and growing investment in Natera signals his conviction in the company's long-term prospects in the rapidly expanding cancer diagnostics market.